Aldeyra Therapeutics, Inc. (ALDX)
1.48
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
1.48
0.00 (0.00%)
After-Hours: 20:00
Aldeyra Therapeutics Free Cash Flow : -22.04M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -22.04M |
| March 31, 2026 | -25.99M |
| December 31, 2025 | -33.35M |
| September 30, 2025 | -40.08M |
| June 30, 2025 | -41.04M |
| March 31, 2025 | -45.71M |
| December 31, 2024 | -43.21M |
| September 30, 2024 | -30.67M |
| June 30, 2024 | -30.72M |
| March 31, 2024 | -30.86M |
| December 31, 2023 | -30.33M |
| September 30, 2023 | -42.06M |
| June 30, 2023 | -46.61M |
| March 31, 2023 | -53.21M |
| December 31, 2022 | -56.65M |
| September 30, 2022 | -57.00M |
| June 30, 2022 | -52.86M |
| March 31, 2022 | -41.97M |
| December 31, 2021 | -42.56M |
| September 30, 2021 | -39.30M |
| June 30, 2021 | -37.11M |
| March 31, 2021 | -35.61M |
| December 31, 2020 | -37.49M |
| September 30, 2020 | -40.40M |
| Date | Value |
|---|---|
| June 30, 2020 | -42.08M |
| March 31, 2020 | -47.32M |
| December 31, 2019 | -44.99M |
| September 30, 2019 | -41.71M |
| June 30, 2019 | -41.57M |
| March 31, 2019 | -35.06M |
| December 31, 2018 | -30.12M |
| September 30, 2018 | -27.38M |
| June 30, 2018 | -24.30M |
| March 31, 2018 | -23.31M |
| December 31, 2017 | -19.41M |
| September 30, 2017 | -18.13M |
| June 30, 2017 | -16.92M |
| March 31, 2017 | -14.87M |
| December 31, 2016 | -15.16M |
| September 30, 2016 | -14.27M |
| June 30, 2016 | -13.70M |
| March 31, 2016 | -12.08M |
| December 31, 2015 | -9.434M |
| September 30, 2015 | -8.030M |
| June 30, 2015 | -6.263M |
| March 31, 2015 | -5.556M |
| December 31, 2014 | -4.776M |
| September 30, 2014 | -3.770M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -75.11M |
| Oncolytics Biotech, Inc. | -26.53M |
| Sangamo Therapeutics, Inc. | -90.46M |
| Sarepta Therapeutics, Inc. | 58.34M |
| Anixa Biosciences, Inc. | -7.117M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -4.589M |
| Cash from Investing (Quarterly) | -0.0231M |
| Cash from Financing (Quarterly) | -15.30M |
| Free Cash Flow Per Share (Quarterly) | -0.0765 |
| Free Cash Flow to Equity (Quarterly) | 10.76M |
| Free Cash Flow to Firm (Quarterly) | -4.612M |
| Free Cash Flow Yield | -24.73% |